September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Association of serum neutralizing antibodies with safety and efficacy outcomes in a Phase 2a trial of rAAV.sFlt-1 in the treatment of wet AMD
Author Affiliations & Notes
  • Elizabeth P Rakoczy
    Centre for Ophthalmology and Visual Sciences, University of Western Australia, Perth, Western Australia, Australia
    Molecular Ophthalmology, Lions Eye Institute, Perth, Western Australia, Australia
  • Chooi-May Lai
    Centre for Ophthalmology and Visual Sciences, University of Western Australia, Perth, Western Australia, Australia
  • Aaron Magno
    Molecular Ophthalmology, Lions Eye Institute, Perth, Western Australia, Australia
  • Martyn French
    School of Pathology, The University of Western Australia, Perth, Western Australia, Australia
  • Samuel Bradley Barone
    Avalanche Biotechnologies, San Francisco, California, United States
  • Steven D Schwartz
    Jules Stein Eye Institute, University of California, Los Angeles, California, United States
  • Mark Blumenkranz
    Byers Eye Institute, Stanford University, Palo Alto, California, United States
  • Mariapia Degli-Esposti
    Centre for Ophthalmology and Visual Sciences, University of Western Australia, Perth, Western Australia, Australia
  • Ian J Constable
    Centre for Ophthalmology and Visual Sciences, University of Western Australia, Perth, Western Australia, Australia
  • Footnotes
    Commercial Relationships   Elizabeth Rakoczy, Avalanche Biotechnologies (C), Avalanche Biotechnologies (P); Chooi-May Lai, Avalanche Biotechnologies (F), Avalanche Biotechnologies (P); Aaron Magno, Avalanch (F); Martyn French, None; Samuel Barone, Avalanche Biotechnologies (E), Avalanche Biotechnologies (I); Steven Schwartz, Avalanche Biotechnologies (I); Mark Blumenkranz, Avalanche Biotechnologies (I); Mariapia Degli-Esposti, None; Ian Constable, Avalanche Biotechnologies (F), Avalanche Biotechnologies (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 526. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth P Rakoczy, Chooi-May Lai, Aaron Magno, Martyn French, Samuel Bradley Barone, Steven D Schwartz, Mark Blumenkranz, Mariapia Degli-Esposti, Ian J Constable; Association of serum neutralizing antibodies with safety and efficacy outcomes in a Phase 2a trial of rAAV.sFlt-1 in the treatment of wet AMD. Invest. Ophthalmol. Vis. Sci. 2016;57(12):526.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: To explore relationship between safety and efficacy outcomes and immunological status following subretinal rAAV.sFlt-1 injection at one year post-treatment.

Methods : Subjects were randomized to receive subretinal rAAV.sFlt-1 (10E11vg, n=21) or control (n=10). All subjects were able to receive intravitreal ranibizumab (RBZ) retreatment according to protocol-driven criteria for worsening wet AMD. Ophthalmic safety, immune response to AAV2, and routine laboratory safety tests were assessed.

Results : No serious adverse events (AE) related to rAAV.sFlt-1 were observed at one year. Transient AEs were: subretinal hemorrhage, inflammation, and increased IOP. Ten of eleven phakic subjects developed post vitrectomy cataract which was treated by extraction and lens implantation. In the rAAV.sFlt-1 treated group the mean BCVA increased by +2.2 ETDRS letters and mean CPT increased by +27μm from baseline (BL). Eleven of 21 rAAV.sFlt-1 treated subjects required ≤2 RBZ rescue injections. Of these, 10 had AAV2 neutralizing antibodies (nAb) present at BL. For these 11 subjects, mean CPT remained unchanged (BL 338μm vs 1 yr 343μm) and mean BCVA increased by +6.7 ETDRS letters. The rAAV2.sFlt-1 treated subjects requiring >2 RBZ injections (n=10) lost a mean of -2.7 ETDRS letters, while mean CPT increased by +51μm (BL 406μm vs 1 yr 456μm), and two had nAb present at BL. Controls showed a mean -9.3 ETDRS letter loss and -85μm CPT decrease (BL 418μm vs 1 yr 333μm). They received a mean of 3.6 (median=4) rescue RBZ injections compared to a mean of 3.1 (median=2) injections for the rAAV.sFlt-1 treated group. Three controls had nAbs present at BL. Of the 21 rAAV.sFlt-1 treated subjects, 5 demonstrated transient and 3 showed sustained increases in nAb titer.

Conclusions : In this phase 2a study, subretinal rAAV.sFlt-1 was well-tolerated with a favorable safety profile. At one year following rAVV.sFlt-1, a subset of subjects had encouraging signs of a response with vision gain and fewer injections received while mean foveal thickness showed minimal change. Presence of pre-existing serum neutralizing antibodies did not appear to affect clinical outcomes.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×